[Involvement of angiotensin II in pathogenesis of hypertension and target organ damage].
Okigaki
Mitsuhiko
M
Department of Internal Medicine II, Kansai Medical University.
Iwasaka
Toshiji
T
D015906:Angioplasty, Balloon, Coronary; D000804:Angiotensin II / Q000502:physiology*; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000209:etiology; D006332:Cardiomegaly / Q000209:etiology; D002986:Clinical Trials as Topic; D023903:Coronary Restenosis / Q000517:prevention & control; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology*; D006977:Hypertension, Renal / Q000209:etiology; D007333:Insulin Resistance; D019808:Losartan / Q000627:therapeutic use; D017257:Ramipril / Q000627:therapeutic use; D044140:Receptor, Angiotensin, Type 1 / Q000502:physiology
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D044140:Receptor, Angiotensin, Type 1; D000804:Angiotensin II; D019808:Losartan; D017257:Ramipril